Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib

Anacetrapib, a Novel CETP Inhibitor: Pursuing a New Approach to Cardiovascular Risk Reduction

(2011) D E Gutstein et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)

(2011) et al.   EUROPEAN HEART JOURNAL

Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib

(2011) Ronald M. Krauss et al.   JOURNAL OF LIPID RESEARCH

Seven Direct Methods for Measuring HDL and LDL Cholesterol Compared with Ultracentrifugation Reference Measurement Procedures

(2010) W. G. Miller et al.   CLINICAL CHEMISTRY

Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease

(2010) Christopher P. Cannon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Design of the DEFINE trial: Determining the EFficacy and Tolerability of CETP INhibition with AnacEtrapib

(2009) Christopher P. Cannon et al.   AMERICAN HEART JOURNAL

Major Lipids, Apolipoproteins, and Risk of Vascular Disease

(2009) The Emerging Risk Factors Collaboration*   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients

(2008) Daniel Bloomfield et al.   AMERICAN HEART JOURNAL

Standardization of Measurements for Cholesterol, Triglycerides, and Major Lipoproteins

(2008) G. Russell Warnick et al.   Labmedicine